Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab.
作者信息
Reardon Kara, Levin Jarad, Levin Carly
机构信息
Department of Dermatology at the University of Oklahoma, Oklahoma City, Oklahoma.
Texas Tech University Health Sciences Center, El Paso, Texas.
出版信息
JAAD Case Rep. 2021 Jan 10;9:7-8. doi: 10.1016/j.jdcr.2020.12.036. eCollection 2021 Mar.
Abstract
摘要
相似文献
1
Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab.伴有1型单纯疱疹病毒重叠感染的重度化脓性汗腺炎及对司库奇尤单抗的临床反应性
JAAD Case Rep. 2021 Jan 10;9:7-8. doi: 10.1016/j.jdcr.2020.12.036. eCollection 2021 Mar.
2
A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26.在化脓性汗腺炎中发现一种新的辅助性 T 细胞 17 细胞因子：白细胞介素-26 的抗菌和促炎作用。
Br J Dermatol. 2019 Nov;181(5):1038-1045. doi: 10.1111/bjd.17854. Epub 2019 Jun 23.
3
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.在化脓性汗腺炎患者中，白细胞介素（IL）-17 血清水平升高：提示抗 IL-17 药物治疗的意义。
J Am Acad Dermatol. 2017 Apr;76(4):670-675. doi: 10.1016/j.jaad.2016.10.042. Epub 2016 Dec 29.
4
Staphylococcus aureus Carriage Status in Patients with Hidradenitis Suppurativa: An Observational Cohort Study in a Tertiary Referral Hospital in Athens, Greece.金黄色葡萄球菌携带者在化脓性汗腺炎患者中的状况：希腊雅典一家三级转诊医院的观察性队列研究。
Dermatology. 2020;236(1):31-36. doi: 10.1159/000504537. Epub 2019 Dec 4.
5
Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.阿达木单抗对中重度化脓性汗腺炎患者 Th17 淋巴细胞和中性粒细胞相关炎症血清标志物的影响。
Cytokine. 2018 Mar;103:20-24. doi: 10.1016/j.cyto.2017.12.020. Epub 2017 Dec 28.
6
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.评估化脓性汗腺炎临床应答（HiSCR）作为化脓性汗腺炎治疗的临床终点的有效性、反应性和有意义性。
Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.
7
Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.化脓性汗腺炎临床反应在化脓性汗腺炎患者评估中的可靠性
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2254-2256. doi: 10.1111/jdv.15163. Epub 2018 Jul 17.
8
Inflammatory Mechanisms in Hidradenitis Suppurativa.化脓性汗腺炎的炎症机制
Dermatol Clin. 2016 Jan;34(1):51-8. doi: 10.1016/j.det.2015.08.004.
9
The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.血清促炎细胞因子、C 反应蛋白和红细胞沉降率升高对化脓性汗腺炎患者的临床意义。
Mediators Inflamm. 2017;2017:2450401. doi: 10.1155/2017/2450401. Epub 2017 Jul 10.
10
Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa.化脓性汗腺炎皮损中抗菌药物耐药模式。
J Am Acad Dermatol. 2017 Feb;76(2):309-313.e2. doi: 10.1016/j.jaad.2016.08.001. Epub 2016 Oct 11.
引用本文的文献
1
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
2
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
3
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
4
An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.抗白细胞介素-17A单克隆抗体司库奇尤单抗治疗难治性化脓性汗腺炎：病例系列
Skin Appendage Disord. 2022 Jul;8(4):342-345. doi: 10.1159/000521860. Epub 2022 Feb 9.
5
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
6
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
7
Insights into the Pathogenesis of HS and Therapeutical Approaches.化脓性汗腺炎发病机制及治疗方法的见解。
Biomedicines. 2021 Sep 6;9(9):1168. doi: 10.3390/biomedicines9091168.
本文引用的文献
1
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
2
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.在化脓性汗腺炎患者中，白细胞介素（IL）-17 血清水平升高：提示抗 IL-17 药物治疗的意义。
J Am Acad Dermatol. 2017 Apr;76(4):670-675. doi: 10.1016/j.jaad.2016.10.042. Epub 2016 Dec 29.
Zotero 插件